Market closed

iTeos Therapeutics/$ITOS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About iTeos Therapeutics

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

Ticker

$ITOS
Trading on

Industry

Biotechnology

Employees

157

ITOS Metrics

BasicAdvanced
$271M
Market cap
-
P/E ratio
-$3.14
EPS
1.39
Beta
-
Dividend rate
$271M
1.39
$18.75
$7.09
535K
14.801
14.438
0.661
0.875
-13.04%
-19.72%
8.189
0.43
0.43
-2.382
-47.37%
81.89%
-30.50%
99.06%

What the Analysts think about ITOS

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for iTeos Therapeutics stock.

ITOS Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ITOS Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ITOS

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for iTeos Therapeutics stock?

iTeos Therapeutics (ITOS) has a market cap of $271M as of December 24, 2024.

What is the P/E ratio for iTeos Therapeutics stock?

The price to earnings (P/E) ratio for iTeos Therapeutics (ITOS) stock is 0 as of December 24, 2024.

Does iTeos Therapeutics stock pay dividends?

No, iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders as of December 24, 2024.

When is the next iTeos Therapeutics dividend payment date?

iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders.

What is the beta indicator for iTeos Therapeutics?

iTeos Therapeutics (ITOS) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.